Key Points {#FPar1}
==========

Prasugrel at a loading dose of 20 mg and a maintenance dose of 3.75 mg was administered to healthy Japanese elderly and non-elderly subjects. No statistically significant difference was found between the two groups in the pharmacokinetic parameters; however, the antiplatelet effect was higher in elderly than in non-elderly subjects with a statistically significant difference from 24 h after dosing.No serious or clinically severe adverse events were observed in either elderly or non-elderly subjects.

Introduction {#Sec1}
============

Prasugrel, a thienopyridine prodrug, is metabolized in vivo to an active metabolite, R-138727, which binds to P2Y~12~ receptors irreversibly and inhibits adenosine diphosphate (ADP)-induced platelet aggregation \[[@CR1]--[@CR3]\]. Prasugrel is a potent inhibitor of platelet aggregation, with a rapid onset of antiplatelet effect and minimal inter-individual variability compared with clopidogrel \[[@CR4]--[@CR7]\]. In patients undergoing percutaneous coronary intervention, the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) study demonstrated that prasugrel significantly reduced the primary endpoint of myocardial infarction, stroke, and cardiovascular death compared with clopidogrel \[[@CR8]\]. Prasugrel (60-mg loading dose and 10-mg maintenance dose) is used for the reduction of atherothrombotic cardiovascular events in patients undergoing percutaneous coronary intervention in USA, the European Union, and in other countries.

In the TRITON-TIMI 38 \[[@CR8]\], the incidence of bleeding events was increased in elderly patients; however, in that study, the dose of prasugrel (60-mg loading dose and 10-mg maintenance dose) was higher than the approved dose in Japan (20-mg loading dose and 3.75-mg/day maintenance dose), and also aspirin was co-administered. The evaluation of the effect of prasugrel in elderly Japanese subjects is very important because bleeding risk in general is increased with aging \[[@CR9]--[@CR12]\]. In the present study, we compared the pharmacokinetics, pharmacodynamics, and safety of prasugrel monotherapy (20-mg loading dose and 3.75-mg/day maintenance dose) in healthy Japanese elderly and non-elderly subjects.

Methods {#Sec2}
=======

Subjects and Study Design {#Sec3}
-------------------------

This study was conducted as an open-label parallel-group study to compare the pharmacokinetics and pharmacodynamics between elderly (aged \>75 years) and non-elderly healthy Japanese (aged 45--65 years) subjects at the Kitasato University Research Center for Clinical Pharmacology and CPC Clinical Trial Hospital. The study included subjects with a body mass index of ≥18.5 and \<30.0 kg/m^2^ and with blood pressure \<150/95 mmHg. Subjects who met any of the following criteria were excluded from the study: those with a current or past history of a disorder of the central nervous system, circulatory system, respiratory system, hematological or hematopoietic function, digestive system, liver function or kidney function; those with grossly evident petechial hemorrhage; those with a bleeding diathesis or bleeding disorder; those with body weight \<50 kg; and those with laboratory test values exceeding the institutional standard value.

For those who agreed to participate in the present study, investigators performed the screening test during the period between 2 and 30 days before the first dose of the study drug, and for those who were judged eligible, subsequent screening tests were performed both on the day before and on the day of the first dose. Subjects received the 20-mg loading dose of prasugrel on the first day. From days 2 to 7, they received the 3.75-mg/day maintenance dose.

The present study was conducted in accordance with the Declaration of Helsinki in compliance with Good Clinical Practice and with the approval of the institutional review board. Written informed consent to participate in the study was obtained from subjects before their participation in the study.

Pharmacokinetics {#Sec4}
----------------

Blood samples were collected before dosing and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose on day 1, and before dosing and at 0.25, 0.5, 1, 1.5, 2, 4, 6, and 8 h post-dose on day 7 for determination of the plasma concentration of R-138727 (the active metabolite of prasugrel). The analysis was performed using a liquid chromatography-tandem mass spectrometry method with the lower quantification limit of 0.5 ng/mL.

A 5-mL venous blood sample was taken from the antebrachial cutaneous vein of each subject (using a vacuum blood collection tube with EDTA-2K) for all collection points. A 25-μL of 3′-methoxyphenacyl bromide acetonitrile solution was added to each sample, which was mixed by inversion and chilled on ice. After centrifugation of the sample (3000 rpm for 10 min at 4 °C), the obtained plasma was divided into two storage containers (about 1.0 mL each) and sent for drug concentration analysis at a different facility. Component analysis was performed on an Inertsil^®^ ODS-3 high-performance liquid chromatography column (GL Sciences Inc., Torrance, CA, USA) using methanol and 1% formic acid for the mobile phase (flow rate, 0.25 mL/min; injection volume, 5 µL). For mass spectrometry an API4000 quadrupole tandem mass spectrometer (AB SCIEX, Framingham, MA, USA) was used. For chromatogram analysis, the software Analyst, Version 1.4.1 (Applied biosystems/MDS SCIEX, Foster City, CA, USA) program was used to calculate the peak area ratio (Y) for R-138727. The calibration curve was derived by linear regression analysis using the preparation concentration (*X*) with reweighting (1/*X* ^2^); internal standards were employed to achieve quantitative calculations. The linearity of the calibration curve was confirmed by correlation coefficient (*r*) ≥0.9800. The acceptable relative error for values obtained by back-calculation was considered to be ±15% for data above the lower limit of quantification, and between −15.0 and 20.0% for data below the lower limit of quantification.

The following pharmacokinetic parameters were calculated using WinNonlin-Professional, Version 5.2 (Pharsight Corporation, Mountain View, CA, USA): area under the plasma concentration--time curve up to infinity, area under the plasma concentration--time curve up to the last quantifiable time, area under the plasma concentration--time curve during a dosing interval, maximum plasma concentration, time to reach maximum plasma concentration, and terminal elimination half-life.

For the comparison of pharmacokinetic parameters, log-transformed values of each parameter (for time to reach maximum plasma concentration, untransformed values) were used, and the ratios of geometric means (for time to reach maximum plasma concentration, differences in the arithmetic means) and 90% confidence interval (CI) between each age group were calculated. If the 90% CI did not contain 1, the results were considered statistically significant.

Pharmacodynamics {#Sec5}
----------------

Blood samples were collected on day 1 (before dosing, and at 1, 4, 8, and 24 h post-dose), and day 7 (before dosing, and at 4 and 8 h post-dose). For all timepoints, a 4.5-mL venous blood sample was taken from the antebrachial cutaneous vein of each subject (using a vacuum blood collection tube with 3.8% sodium citrate). The pharmacodynamic measurements were determined by the light transmission method in response to 5 and 20 µM of ADP. Inhibition of platelet aggregation (IPA) at each blood sampling timepoint was calculated using the following formula:$$\documentclass[12pt]{minimal}
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For IPA obtained at each blood sampling point for each subject, the arithmetic mean was calculated. The differences in the arithmetic mean IPA and two-sided 90% CI between the elderly and non-elderly groups were used to compare the inhibitory effect of prasugrel in the two groups. If the 90% CI did not contain 0, the results were considered statistically significant.

Safety {#Sec6}
------

The safety of prasugrel was evaluated by assessing the incidence of adverse events (AEs) from the time of administration of the study drug until the follow-up test conducted 9--15 days after the last dosing. An AE was defined as the occurrence or worsening of subjective or objective symptoms, or an abnormal change in laboratory test values, in a subject who received prasugrel, which does not necessarily have a causal relationship with the drug. Adverse events were graded according to their severity, as mild, moderate, and severe. The following were considered serious AEs: (1) death, (2) conditions potentially leading to death, (3) conditions requiring hospitalization or prolonged hospitalization for their treatment, (4) disability, (5) conditions potentially leading to disability, (6) conditions similar to 1--5 in severity, and (7) congenital disease or abnormality in a later generation. Hemorrhagic events were considered important AEs in the present study.

Statistical Analysis {#Sec7}
--------------------

Based on previous clinical studies, we estimated the standard deviations of IPA as 8 and 10%, and the difference in the arithmetic mean IPA between the elderly and non-elderly groups as 10%. Under these assumptions, we twice performed a *t* test with a one-sided significance level of 0.05 for 40 subjects; we confirmed high statistical power (97.9 and 87.5%). Additionally, even if there were two dropouts, the statistical power would still be adequate, at 97.3 and 85.5%, respectively. Consequently, the number of subjects was determined as 40. The time course of the plasma concentration of R-138727 was plotted. Pharmacokinetic parameters were estimated by non-compartmental analysis methods.

Patient demographical characteristics were evaluated as follows: for categorical variables, frequency tables by age were generated. For quantitative variables, summary statistics (number of subjects, arithmetic means, standard deviations, and median/minimum/maximum values) were calculated. SAS System Release, Version 8.2 (SAS Institute Inc., Cary, NC, USA) was used for data collection and analysis.

Results {#Sec8}
=======

Disposition of Subjects {#Sec9}
-----------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, 120 subjects were prescreened and then 57 subjects were screened for eligibility; 47 subjects were subsequently enrolled (23 elderly and 24 non-elderly) and received the study drug. However, one subject in the non-elderly group discontinued the study drug because of an AE, fecal occult blood, on day 2 after dosing.Fig. 1Patient flow diagram

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the subjects. The mean age of the elderly group was 77.6 ± 2.9 years and the mean age of the non-elderly group was 58.2 ± 5.5 years. The proportion of current smokers was 8.7 and 29.2% in the elderly and non-elderly groups, respectively. There was no statistically significant difference in the other baseline characteristics between the two groups.Table 1Baseline characteristics of subjectsCharacteristicElderlyNon-elderlyNumber of subjects2324Age (years)^a^77.6 ± 2.958.2 ± 5.5 Median77.060.0 Minimum, maximum75, 8648, 64Body weight (kg)^a^58.8 ± 8.060.4 ± 7.5 Median57.559.6 Minimum, maximum50.1, 83.650.8, 78.1BMI (kg/m^2^)^a^24.0 ± 2.823.5 ± 3.0 Median24.723.5 Minimum, maximum20.0, 29.718.7, 29.7Male sex \[*n* (%)\]14 (60.9)15 (62.5)Smoking habits \[*n* (%)\] Non-smoker17 (73.9)15 (62.5) Current smoker2 (8.7)7 (29.2) Ex-smoker4 (17.4)2 (8.3)*BMI* body mass index^a^Values are expressed as the mean ± standard deviation, unless otherwise noted

Pharmacokinetics {#Sec10}
----------------

The plasma concentration of R-138727 increased rapidly after administration in both groups, reached a maximum at 30 min after administration, and then decreased rapidly, both on days 1 and 7 (Fig. [2](#Fig2){ref-type="fig"}a, b, respectively). The plasma concentration curves were almost superimposable between elderly and non-elderly subjects at 1.5 h after dosing. By 24 h after the loading dose, or 8 h after the maintenance dose, the plasma concentration was near the lower quantifiable limit in both groups.Fig. 2Plasma concentrations of R-138727, the active metabolite of prasugrel, in elderly and non-elderly subjects on **a** day 1 and **b** day 7. Data are expressed as the arithmetic mean ± standard deviation

The pharmacokinetic parameters of R-138727 are shown in Table [2](#Tab2){ref-type="table"}. The area under the plasma concentration--time curve up to the last quantifiable time values, as expressed as geometric mean (percentage coefficient of variation), in elderly and non-elderly subjects were 173.5 (34.7) ng·h/mL and 174.5 (35.9) ng·h/mL, respectively, after the loading dose (day 1), and 26.0 (31.2) ng·h/mL and 24.7 (38.8) ng·h/mL, respectively, after the maintenance dose (day 7). Maximum plasma concentration values in elderly and non-elderly subjects were 134.3 (62.1) ng/mL and 153.3 (62.1) ng/mL, respectively, on day 1, and 25.2 (44.7) ng/mL and 24.9 (68.7) ng/mL, respectively, on day 7. The estimated ratios of the geometric mean values for area under the plasma concentration--time curve up to the last quantifiable time between elderly and non-elderly subjects (as calculated by the value in elderly subjects/value in non-elderly subjects) and its 90% CI were 0.994 (0.837--1.181) after the loading dose and 1.055 (0.891--1.250) after the maintenance dose, showing no statistically significant difference between the two groups. The ratios for maximum plasma concentration also showed no significant difference for both groups after the loading dose \[0.876 (0.658--1.166)\] and maintenance dose \[1.011 (0.777--1.317)\]. Taken together, these data indicated that there was no statistically significant difference in the pharmacokinetic parameters of elderly subjects compared with non-elderly subjects.Table 2Pharmacokinetic parameters for R-138727, the active metabolite of prasugrelElderly (*n* = 23)Non-elderly (*n* = 23)Ratio^a^ (90% CI)Day 1 AUC~last~ (ng·h/mL)173.5 (34.7)174.5 (35.9)0.994 (0.837 to 1.181) AUC~0--inf~ (ng·h/mL)179.0 (34.6)178.8 (36.1)1.001 (0.843 to 1.189) *C* ~max~ (ng·h/mL)134.3 (62.1)153.3 (62.1)0.876 (0.658 to 1.166) *t* ~max~ (h)0.57 (0.27)0.59 (0.23)−0.019 (−0.145 to 0.107) *t* ~1/2~ (h)4.4 (60.9)3.5 (90.3)1.262 (0.903 to 1.763)Day 7 AUC~last~ (ng·h/mL)26.0 (31.2)24.7 (38.8)1.055 (0.891 to 1.250) AUC~tau~ (ng·h/mL)27.1 (30.6)26.2 (36.2)1.033 (0.878 to 1.216) *C* ~max~ (ng/mL)25.2 (44.7)24.9 (68.7)1.011 (0.777 to 1.317) *t* ~max~ (h)0.59 (0.28)0.61 (0.36)−0.022 (−0.181 to 0.138) *t* ~1/2~ (h)1.0 (65.7)0.8 (50.5)1.176 (0.896 to 1.544)Values are geometric mean (percentage coefficient of variation). *t* ~max~ is expressed as arithmetic mean (standard variation)*AUC* ~*last*~ area under the plasma concentration--time curve from time 0 to last measurement, *AUC* ~*tau*~ area under the plasma concentration--time curve over a dosing interval, *AUC* ~*0*--*inf*~ area under the plasma concentration--time curve up to infinity, *CI* confidence interval, *C* ~*max*~ maximum plasma concentration, *t* ~*max*~ time to *C* ~max~, *t* ~*1/2*~ terminal elimination half-life^a^Ratios were the value in elderly subjects/value in the non-elderly subjects

Pharmacodynamics {#Sec11}
----------------

Prasugrel (in response to 20 µM of ADP) inhibited platelet aggregation in both groups (Fig. [3](#Fig3){ref-type="fig"}). The IPA increased rapidly after the loading dose of prasugrel was administered, reaching a maximum of about 50% at 8 h. The inhibitory effect was maintained without attenuation during the maintenance dose administration, with a maximum of about 40% at 4 h.Fig. 3Inhibition of adenosine diphosphate (20 µM)-induced platelet aggregation in elderly and non-elderly subjects. Data are expressed as the arithmetic mean ± standard deviation. \**p* \< 0.05 vs non-elderly subjects. *IPA* inhibition of platelet aggregation

The inhibitory effects on platelet aggregation between the elderly and non-elderly groups were not significantly different up to 8 h after the loading dose. However, the elderly group exhibited a greater inhibitory effect compared with the non-elderly group at 24 h after the loading dose, and at 4 and 8 h after the maintenance dose. The results of the comparison of IPA values are shown in Table [3](#Tab3){ref-type="table"}. The inhibitory effects on platelet aggregation with 5 µM of ADP were similar to those with 20 µM of ADP (Supplementary Table).Table 3Comparison of the inhibition of platelet aggregation values in the elderly and non-elderly groupsTime after dosingElderly (*n* = 23)Non-elderly (*n* = 23)Comparison for both groupsMean (%)95% CIMean (%)95% CIDifference in arithmetic mean90%CIDay 1 1 h36.328.7--44.034.226.4 to 42.12.1−6.8 to 11.0 4 h51.146.8--55.548.543.4 to 53.62.6−2.8 to 8.0 8 h54.850.8--58.851.546.6 to 56.53.3−1.9 to 8.4Day 2 Before dosing50.847.3--54.345.641.9 to 49.35.21.1 to 9.3Day 7 Before dosing38.233.3--43.133.028.1 to 37.85.2−0.4 to 10.8 4 h43.639.5--47.738.534.1 to 42.95.10.24 to 10.0 8 h43.638.7--48.536.032.0 to 40.07.62.5 to 12.7Post-study4.20.5--.91.8−0.8 to 4.32.4−1.2 to 6.1Values are expressed as arithmetic mean*CI* confidence interval

Safety {#Sec12}
------

There were no serious AEs. In the non-elderly group, one subject discontinued the study drug because of fecal occult blood; this event was considered severe but it had resolved without any treatment by the following day. In addition, there were 11 fecal occult blood events (elderly group, seven subjects and non-elderly group, four subjects) and five subcutaneous bleeding events (elderly group, four subjects and non-elderly group, one subject). One oral hematoma and one retinal hemorrhage in the elderly group were also reported. All of the events were considered related to prasugrel treatment, which were transient and required no treatment.

Discussion {#Sec13}
==========

In the previous study of prasugrel, Umemura et al. showed that a single oral administration at a loading dose of up to 30 mg and a multiple administration at a maintenance dose of up to 10 mg/day were tolerated in healthy Japanese subjects \[[@CR13]\]. In the present study, we used prasugrel at the approved dose in Japan (20-mg loading dose and 3.75-mg/day maintenance dose) to compare the pharmacokinetic and pharmacodynamic profiles of prasugrel in healthy Japanese elderly subjects and non-elderly subjects. We found that in the elderly subjects, prasugrel had a higher antiplatelet effect, with a statistically significant difference from 24 h after dosing, despite no significant difference in the pharmacokinetic parameters, compared with non-elderly subjects. No serious or clinically severe AEs were observed in either elderly or non-elderly subjects.

In the baseline characteristics, there was a higher ratio of smokers in the non-elderly subjects. The TRILOGY ACS trial \[[@CR14]\] showed that the P2Y~12~ reaction unit tends to be lower in smokers than in non-smokers. Therefore, we consider that the higher antiplatelet effect observed in the eldery subjects was not caused by the difference in the baseline characteristics.

In a study in the UK \[[@CR15]\] comparing the pharmacokinetics and pharmacodynamics of prasugrel (maintenance dose 5 mg/day for 10 days followed by 10 mg/day for 10 days in combination with aspirin 75 mg) between elderly (aged 65--80 years) and non-elderly (aged 20--39 years) subjects, no difference was found in the pharmacokinetic parameters. However, the maximum platelet aggregation was higher in the elderly subjects; the finding was inconsistent with the results of the pharmacodynamics in the present study. Therefore, it appears that prasugrel does not consistently cause increased pharmacodynamic effects in elderly subjects.

In the PRASFIT-ACS study, a phase III registration study in Japan that compared prasugrel and clopidogrel used in combination with aspirin in patients with acute coronary syndrome who were scheduled to undergo percutaneous coronary intervention, the antiplatelet effect (measured by VerifyNow, Accumetrics, San Diego, CA, USA) in patients aged ≥75 years was comparable to that in the overall study population, according to the subgroup analysis. In addition, the incidence of clinically significant bleeding events was similar to that of clopidogrel \[[@CR16]\]. In the present study, there were no serious or clinically severe AEs in the elderly group.

Conclusion {#Sec14}
==========

Administration of prasugrel at a 20-mg loading dose and a 3.75-mg maintenance dose in healthy Japanese elderly subjects showed no statistically significant difference in the pharmacokinetics but a higher antiplatelet effect, with a statistically significant difference from 24 h after dosing, compared with in non-elderly subjects. No serious or clinically severe AEs were observed.
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